We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Photodynamic Therapy Facilitates Prostate and Pancreatic Cancer Treatment

By HospiMedica International staff writers
Posted on 19 Mar 2012
New technology uses optical fibers that both emit laser light and gather information about a tumor to enable the application of photodynamic therapy (PDT) in internal organs.

Developed by researchers at Lund University (Sweden) and software company SpectraCure (Lund, Sweden), the PDT protocol is based on unique IDOSE software that uses the optical fibers for more than simply emitting light. More...
Intermittently they also gather information about the tumor, which they send back to the laser instrument. In this way, the software can continually calculate the optimal light dose to activate the phonosensitizing drug (and adjust it if necessary), so that the entire tumor can be removed.

The system allows pretreatment planning, including optimal optical fiber positioning and optimal light dose calculation. Once the photosensitizer is activated by sufficient light in the presence of oxygen, highly reactive, short-lived singlet oxygen and cytotoxic oxygen radicals are generated. Singlet oxygen is a very aggressive chemical species and it will very rapidly react with any nearby biomolecules; ultimately, these destructive reactions kill cells through apoptosis or necrosis. It is therefore critical to adjust the dosimetry accurately so that the interstitial PDT treatment of solid tumors does not damage healthy tissue.

“The advantage of laser light is that it appears that side effects can be minimized. With current treatment methods, prostate cancer patients who are cured risk both impotence and incontinence,” said Johannes Swartling, PhD, of Lund University and Chief Technical Officer at SpectraCure, a spinoff of the university. “I think we are about to see a real breakthrough, both for us and for other research groups around the world who conduct research on cancer treatment using laser light.”

PDT is used clinically to treat a wide range of medical conditions, including wet age-related macular degeneration (AMD) and malignant cancers, and is recognized as a treatment strategy, which is both minimally invasive and minimally toxic. While the applicability and potential of PDT has been known for over a hundred years, the development of modern PDT has been a gradual one, involving scientific progress in the fields of photobiology and cancer biology, as well as the development of modern photonic devices, such as lasers and light emitting diodes (LEDs).

Related Links:

Lund University
SpectraCure



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.